AU2019243579B2 - Compositions and methods of detecting and treating Alzheimer's disease - Google Patents

Compositions and methods of detecting and treating Alzheimer's disease Download PDF

Info

Publication number
AU2019243579B2
AU2019243579B2 AU2019243579A AU2019243579A AU2019243579B2 AU 2019243579 B2 AU2019243579 B2 AU 2019243579B2 AU 2019243579 A AU2019243579 A AU 2019243579A AU 2019243579 A AU2019243579 A AU 2019243579A AU 2019243579 B2 AU2019243579 B2 AU 2019243579B2
Authority
AU
Australia
Prior art keywords
nanoscopic
microscopic
bubble
droplet
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019243579A
Other languages
English (en)
Other versions
AU2019243579A1 (en
Inventor
Iman DARYAEI
Emmanuelle Joelle MEUILLET
Evan C. Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microvascular Therapeutics LLC
Original Assignee
Microvascular Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microvascular Therapeutics LLC filed Critical Microvascular Therapeutics LLC
Publication of AU2019243579A1 publication Critical patent/AU2019243579A1/en
Assigned to Microvascular Therapeutics LLC reassignment Microvascular Therapeutics LLC Amend patent request/document other than specification (104) Assignors: MICROVASCUAR THERAPEUTICS LLC
Application granted granted Critical
Publication of AU2019243579B2 publication Critical patent/AU2019243579B2/en
Priority to AU2024205163A priority Critical patent/AU2024205163A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasonic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
AU2019243579A 2018-03-29 2019-03-28 Compositions and methods of detecting and treating Alzheimer's disease Active AU2019243579B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205163A AU2024205163A1 (en) 2018-03-29 2024-07-29 Compositions and methods of detecting and treating alzheimer's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650239P 2018-03-29 2018-03-29
US62/650,239 2018-03-29
PCT/US2019/024713 WO2019191518A1 (en) 2018-03-29 2019-03-28 Compositions and methods of detecting and treating alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205163A Division AU2024205163A1 (en) 2018-03-29 2024-07-29 Compositions and methods of detecting and treating alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2019243579A1 AU2019243579A1 (en) 2020-10-22
AU2019243579B2 true AU2019243579B2 (en) 2024-05-09

Family

ID=68060802

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019243579A Active AU2019243579B2 (en) 2018-03-29 2019-03-28 Compositions and methods of detecting and treating Alzheimer's disease
AU2024205163A Pending AU2024205163A1 (en) 2018-03-29 2024-07-29 Compositions and methods of detecting and treating alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205163A Pending AU2024205163A1 (en) 2018-03-29 2024-07-29 Compositions and methods of detecting and treating alzheimer's disease

Country Status (8)

Country Link
US (1) US20210008204A1 (https=)
EP (1) EP3773500A4 (https=)
JP (2) JP2021519324A (https=)
KR (1) KR20210018789A (https=)
CN (2) CN116173238A (https=)
AU (2) AU2019243579B2 (https=)
CA (1) CA3094377A1 (https=)
WO (1) WO2019191518A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
EP3773500A4 (en) * 2018-03-29 2022-03-16 Microvascular Therapeutics LLC COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
KR102490837B1 (ko) * 2020-03-19 2023-01-19 포항공과대학교 산학협력단 뇌-혈관 장벽 투과성을 증가시키는 방법
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264917B1 (en) * 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US9801959B2 (en) * 2014-06-12 2017-10-31 Microvascuar Therapeutics Llc Phospholipid composition and microbubbles and emulsions formed using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US8877236B2 (en) * 2012-06-28 2014-11-04 Universita Degli Studi Di Milano-Bicocca Liposomes active in-vivo on neurodegenerative diseases
AU2015330824A1 (en) * 2014-10-08 2017-05-25 Ananth Annapragada MRI imaging of amyloid plaque using liposomes
EP3773500A4 (en) * 2018-03-29 2022-03-16 Microvascular Therapeutics LLC COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264917B1 (en) * 1996-10-28 2001-07-24 Nycomed Imaging As Targeted ultrasound contrast agents
US9801959B2 (en) * 2014-06-12 2017-10-31 Microvascuar Therapeutics Llc Phospholipid composition and microbubbles and emulsions formed using same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C. BALDUCCI ET AL: "Multifunctional Liposomes Reduce Brain -Amyloid Burden and Ameliorate Memory Impairment in Alzheimer's Disease Mouse Models", THE JOURNAL OF NEUROSCIENCE, vol. 34, no. 42, 15 October 2014, US, pages 14022 - 14031. *
ERIC A. TANIFUM ET AL: "Intravenous Delivery of Targeted Liposomes to Amyloid-β Pathology in APP/PSEN1 Transgenic Mice", PLOS ONE, vol. 7, no. 10, 31 October 2012 (2012-10-31), pages e48515, XP055477119, DOI: 10.1371/journal.pone.0048515 *
LOCKHART ET AL: "Imaging Alzheimer's disease pathology: one target, many ligands", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 23-24, 1 December 2006 (2006-12-01), pages 1093 - 1099. *
Mai et al, Sensors and Actuators B, September 2017 (available online), Vol 255, pages 2126-2135 (Year: 2017) *

Also Published As

Publication number Publication date
KR20210018789A (ko) 2021-02-18
CN112384202B (zh) 2023-03-21
US20210008204A1 (en) 2021-01-14
CN112384202A (zh) 2021-02-19
AU2019243579A1 (en) 2020-10-22
AU2024205163A1 (en) 2024-08-15
JP2025000828A (ja) 2025-01-07
CA3094377A1 (en) 2019-10-03
CN116173238A (zh) 2023-05-30
EP3773500A1 (en) 2021-02-17
JP2021519324A (ja) 2021-08-10
EP3773500A4 (en) 2022-03-16
WO2019191518A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
AU2019243579B2 (en) Compositions and methods of detecting and treating Alzheimer's disease
CN100563718C (zh) 用于反差成像的充气微囊组件
RU2528104C2 (ru) Носитель лекарственного средства, обеспечивающий контрастное усиление при мрт
CN1897978B (zh) 具有用于反差成像的活性组分的充气微囊组件
US12226529B2 (en) Stable nanolipoprotein particles and related compositions methods and systems
Hussey et al. Efficient delivery of streptavidin to mammalian cells: clathrin-mediated endocytosis regulated by a synthetic ligand
CA2924018C (en) Cell-specific targeting using nanostructured delivery systems
CN102970977A (zh) 用于药物或显像剂的脂质双层载体
ES2965028T3 (es) Producto liofilizado y suspensión de microvesículas llenas de gas
CN103370059A (zh) 一种药物递送装置
US20110059020A1 (en) Liposome composition, and diagnostic contrast agent, therapeutic enhancer, and pharmaceutical composition using the same
JP5147699B2 (ja) タンパク質ナノ粒子およびその使用
US20110190623A1 (en) Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy
US20240148914A1 (en) Compositions and methods of detecting and treating thrombosis and vascular plaques
CN103429226A (zh) 囊泡组合物
US20110104258A1 (en) Technique for drug and gene delivery to the cell cytosol
Liu et al. Sinapultide-loaded lipid microbubbles and the stabilization effect of sinapultide on the shells of lipid microbubbles
JP5463548B2 (ja) 超音波治療用リポソーム及び超音波治療促進用リポソーム
US20260014283A1 (en) Ultrasound-sensitive peptide particles for spatially resolved molecule delivery and methods of using the same
Arya et al. Nanodisc: a new epoch in the study of membrane proteins and as an emerging drug delivery system
US20250177557A1 (en) Methods of producing microbubble drug conjugates, viral gene therapy microbubble conjugates and targeted microbubbles
McCarthy Fibrin Targeting Microbubbles for the Detection of Nascent Surgical Adhesions
CN121846311A (zh) 一种超声微泡-载氯苯唑酸纳米粒复合给药系统及其制备方法和应用

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MICROVASCULAR THERAPEUTICS LLC

Free format text: FORMER NAME(S): MICROVASCUAR THERAPEUTICS LLC

FGA Letters patent sealed or granted (standard patent)